Subscribe to our Email Alerts

Amplia Therapeutics welcomes Garvan paper highlighting benefits of FAK inhibition in pancreatic cancer models

Amplia Therapeutics Ltd (ASX:ATX) welcomes the publication by the Garvan Institute of Medical Research of a key paper describing the fundamental biology underpinning the company’s planned Phase 2 clinical trial in pancreatic cancer patients.

To view the media story please click here.